Loading organizations...
§ Private Profile · 2660 Patton Road Roseville, MN 55113
Rebiotix is a company.
Rebiotix has raised $25.0M across 1 funding round.
Key people at Rebiotix.
Rebiotix has raised $25.0M in total across 1 funding round.
Rebiotix is a biotechnology company focused on the development of human microbe drugs and microbiota therapies. The company utilizes a distinct approach to address various gastrointestinal diseases, leveraging the potential of the human microbiome to create novel treatment modalities. Its therapeutic candidates are designed to restore microbial balance and function within the gut.
The company was founded in 2011 by Lee Jones, driven by the insight to advance microbiota restoration as a viable therapeutic strategy. This foundational premise aimed to transform the treatment landscape for patients suffering from conditions rooted in microbial dysbiosis. Jones’s leadership established the company’s early focus on clinical-stage development in this nascent field.
Rebiotix's product pipeline is directed towards patients experiencing debilitating gastrointestinal illnesses that currently lack adequate treatment options. The long-term vision centers on bringing these innovative microbiome-based therapies through clinical development to ultimately provide new solutions that improve patient outcomes and quality of life.
Key people at Rebiotix.
Rebiotix has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series B in August 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 4, 2014 | $25M Series B | — | — | Announced |
Rebiotix has raised $25.0M in total across 1 funding round.
Rebiotix is a biotechnology company specializing in microbiome-based therapies to treat challenging diseases, particularly recurrent *Clostridium difficile* (C. diff) infections, by restoring the human gut microbiome using its proprietary Microbiota Restoration Therapy (MRT™) platform.[1][2][3] The company develops investigational drugs like RBX2660, a non-antibiotic therapy in late-stage (Phase 3) clinical trials that has received FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations, targeting patients with recurrent C. diff, inflammatory bowel disease, and other microbiome-related conditions.[2][3][5] Acquired by Ferring Pharmaceuticals, Rebiotix serves healthcare providers and patients facing antibiotic-resistant infections, addressing the urgent need for non-antibiotic solutions amid rising C. diff mortality (nearly 30,000 US deaths annually).[3][5] Its growth momentum includes completing enrollment in the first-ever pivotal Phase 3 microbiome trial (over 300 patients) and positive preliminary data, positioning it as a pioneer in standardized, ready-to-use live microbe therapies.[3][5][6]
Rebiotix was founded in 2011 by Lee A. Jones (CEO), Michael Berman, and Erwin A. Kelen in Roseville, Minnesota, with a mission to harness the human microbiome for treating complex diseases, starting with C. diff as an urgent threat.[1][3][5] The idea emerged from recognizing antibiotics' role in disrupting the microbiome and causing recurrences, prompting development of the MRT™ platform to deliver diverse, live human-derived microbes for restoration.[2][3] Early traction built through a deep clinical pipeline, culminating in FDA designations for RBX2660 and its 2018 acquisition by Ferring Pharmaceuticals, which amplified resources for global development.[2][5] Pivotal moments include positive Phase 3 preliminary data (world's first for a microbiome therapy) and trial enrollment completion in 2020.[3][5]
Rebiotix stands out in the microbiome field through these key strengths:
Rebiotix rides the microbiome therapeutics wave, a frontier in biotech shifting from antibiotics to live biotherapeutics amid rising antimicrobial resistance and C. diff's status as a CDC "urgent threat."[3][5] Timing aligns with growing recognition of the gut microbiome's role in diseases (e.g., 10-15% of European hospital infections are recurrent C. diff), fueled by advances in culturing, AI design, and delivery tech.[3][4] Market forces like FDA incentives and demand for non-antibiotic options favor it, with Rebiotix influencing the ecosystem by validating MRT™ as a scalable model—proven in the largest randomized Phase 3 microbiome trial—and partnering for broader applications like maternal health.[4][5] As part of Ferring, it accelerates industry adoption of microbiome drugs, potentially transforming gastroenterology and beyond.[2][6]
Rebiotix is poised for regulatory milestones, with Phase 3 RBX2660 data supporting FDA submission soon after 2020 enrollment and positive results, potentially yielding the first approved microbiome therapy.[3][5][6] Trends like AI-driven consortia and expansions into women's health (via MyBiotics) will shape its path, alongside pipeline maturation for IBD and resistance issues.[4] Its influence may evolve from C. diff pioneer to microbiome platform leader within Ferring, driving paradigm shifts in precision medicine. This builds on its founding vision: revolutionizing treatments through the microbiome's untapped power.[3]
